Roche: CHMP recommends Columvi for diffuse lymphoma

(CercleFinance.com) - Roche has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended approval of Columvi (glofitamab), in combination with GemOx for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), who are ineligible for autologous stem cell transplantation.


This recommendation is based on a Phase III study showing a significant improvement in overall survival compared with standard treatment.

A decision from the European Commission is expected 'in the near future'.


Copyright (c) 2025 CercleFinance.com. All rights reserved.